FDA Approval of Auvelity for Alzheimer’s Agitation Sends Axsome Surging 12%
Axsome Therapeutics (AXSM) shares jumped 11.99% on Thursday after the U.S. Food and Drug Administration (FDA) approved Auvelity for the treatment of agitation associated with Alzheimer’s disease. The landmark decision, which arrived on the drug's scheduled PDUFA action date, makes Auvelity the first non-antipsychotic medication approved for this specific indication, driving the stock to a price of $206.00.
FDA Greenlights Major Label Expansion
Axsome Therapeutics (AXSM) is the standout performer in Thursday's session, surging +11.99% to $206.00 and significantly outperforming the S&P 500, which rose a modest 0.99%. The catalyst for the move is the FDA's approval of Auvelity (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer's disease.
This approval marks a critical label expansion for Auvelity, which was originally approved in 2022 for major depressive disorder. The FDA's decision followed a Priority Review and was supported by data from the Phase 3 ADVANCE-1 and ACCORD-2 trials. In these studies, Auvelity demonstrated a statistically significant improvement in agitation symptoms compared to a placebo, while maintaining a safety profile that matched the placebo in terms of discontinuation rates due to adverse events.
Addressing a Massive Unmet Need
Agitation is one of the most common and distressing complications of Alzheimer’s disease, affecting up to 76% of the estimated 7 million Americans living with the condition. Symptoms can range from restlessness and pacing to verbal and physical aggression, often leading to earlier nursing home placement and increased caregiver burden.
By securing the first-ever approval for a non-antipsychotic treatment in this space, Axsome has positioned Auvelity as a first-in-class therapy. Unlike traditional antipsychotics, which are often used off-label and carry significant safety warnings for elderly patients with dementia, Auvelity targets the NMDA and sigma-1 receptors to modulate neurotransmission without the same sedative or motor side effects.
Analyst Sentiment and Market Impact
Wall Street had been increasingly bullish leading up to today's PDUFA date. Analysts at UBS recently maintained a Buy rating and raised their price target to $259, citing "high conviction" in the drug's approvability. The market response today reflects the realization of a multi-billion-dollar commercial opportunity, as Axsome prepares to expand its sales force to approximately 600 representatives to support the launch.
The stock's move today is part of a broader trend of outperformance for the biotech firm, which has gained nearly 15% over the last month in anticipation of this regulatory milestone. Trading volume for AXSM reached 879.2K shares by mid-afternoon, as institutional buyers reacted to the news.
Looking Ahead
Investors will not have to wait long for further updates. Axsome is scheduled to report its first-quarter 2026 financial results before the market opens on Monday, May 4. Management is expected to provide detailed guidance on the commercial rollout of the new Alzheimer's agitation indication during the subsequent earnings call. Additionally, the company will host a dedicated webcast on Friday, May 1, at 8:00 AM ET to discuss the FDA approval in greater detail.
Key Takeaways
- Axsome shares rose 11.99% to $206.00 following the FDA approval of Auvelity for Alzheimer’s disease agitation.
- Auvelity is now the first non-antipsychotic drug approved for this indication, targeting a market of 7 million U.S. patients.
- The approval was based on successful Phase 3 ADVANCE-1 and ACCORD-2 trials, showing significant symptom improvement over placebo.
- The company is scheduled to report Q1 2026 earnings on Monday, May 4, where launch details are expected to be a primary focus.